Recently Viewed
Clear All
Quality Score
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
₹29,473 Cr
147.17
6.98
37.17
0.61
4.15 %
6.64 %
0.15 %
78.34
3.71
₹4,740.52 Cr
₹7,641.62 Cr
₹3,691.33 Cr
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
---|---|---|---|---|---|---|---|
Laurus Labs
| -9.37 | -2.30 | 14.59 | 39.19 | -0.23 | 43.99 | -- |
BSE Healthcare
| -11.69 | -6.28 | -6.00 | 12.99 | 17.86 | 22.52 | 9.66 |
BSE Mid Cap
| -14.35 | -6.28 | -9.92 | 2.49 | 17.89 | 20.27 | 13.97 |
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
---|---|---|---|---|---|---|---|
Laurus Labs
| 39.18 | 14.64 | -30.37 | 52.49 | 379.50 | -6.06 | -29.66 |
BSE Mid Cap
| 25.84 | 45.53 | 1.38 | 39.18 | 19.87 | -3.05 | -13.31 |
BSE Healthcare
| 43.09 | 36.97 | -12.10 | 20.87 | 61.45 | -3.55 | -5.89 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
--
--Min --Median --Max
--
--Min --Median --Max
--
Earnings Yield (%) = EBIT / Enterprise value
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | P/E Ratio | ROE |
---|---|---|---|---|
1,323.05 | 37,286.93 | -- | -15.04 | |
184.90 | 24,499.83 | 629.82 | 0.67 | |
1,089.65 | 27,701.76 | 99.21 | 13.86 | |
690.35 | 27,803.23 | 55.44 | 11.04 |
Laurus Labs Limited, together with its subsidiaries, manufactures and sells medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company offers Generics APIs for advanced intermediates for anti-retroviral (ARV),... antidiabetic, cardiovascular, anti-asthma, ophthalmology, oncology, gastroenterology, and hepatitis C therapeutic areas. It also provides oral solid formulations for ARVs, anti-diabetic, cardiovascular, and PPIs. In addition, the company offers contract development and manufacturing organizational services; and biotechnology services used in the nutraceutical, dietary supplements, alternate food proteins, and cosmeceutical products. Further, the company develops novel enzymatic solutions for industrial biotechnology, and animal origin free recombinant proteins and enzymes for biopharma; and offers business support services for pharmaceuticals field. Laurus Labs Limited was incorporated in 2005 and is based in Hyderabad, India. Read more
2005
Ravindranath Kancherla
--
Vishakhapatnam, Andhra Pradesh
Looking for more details about Laurus Labs Ltd.’s IPO? Explore our IPO Details page.
The total asset value of Laurus Labs Ltd stood at ₹ 8,729 Cr as on 31-Dec-24
The share price of Laurus Labs Ltd is ₹546.20 (NSE) and ₹546.55 (BSE) as of 14-Feb-2025 IST. Laurus Labs Ltd has given a return of -0.23% in the last 3 years.
Laurus Labs Ltd has a market capitalisation of ₹ 29,473 Cr as on 14-Feb-2025. As per Value Research classification, it is a Mid Cap company.
The P/B ratio of Laurus Labs Ltd is 6.98 times as on 14-Feb-2025, a 101% premium to its peers’ median range of 3.48 times.
The P/E ratio of Laurus Labs Ltd is 147.17 times as on 14-Feb-2025, a 296% premium to its peers’ median range of 37.17 times.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Laurus Labs Ltd and enter the required number of quantities and click on buy to purchase the shares of Laurus Labs Ltd.
Laurus Labs Limited, together with its subsidiaries, manufactures and sells medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company offers Generics APIs for advanced intermediates for anti-retroviral (ARV), antidiabetic, cardiovascular, anti-asthma, ophthalmology, oncology, gastroenterology, and hepatitis C therapeutic areas. It also provides oral solid formulations for ARVs, anti-diabetic, cardiovascular, and PPIs. In addition, the company offers contract development and manufacturing organizational services; and biotechnology services used in the nutraceutical, dietary supplements, alternate food proteins, and cosmeceutical products. Further, the company develops novel enzymatic solutions for industrial biotechnology, and animal origin free recombinant proteins and enzymes for biopharma; and offers business support services for pharmaceuticals field. Laurus Labs Limited was incorporated in 2005 and is based in Hyderabad, India.
The promoter of Laurus Labs Ltd is M/s. NSN Holdings (Represented by its Managing Partner, Dr. Satyanarayana Chava). M/s. NSN Holdings (Represented by its Managing Partner, Dr. Satyanarayana Chava) owns 23.02 per cent of the total equity. The chairman of the company is Ravindranath Kancherla ..
The promoters of Laurus Labs Ltd have pledged 0.74% of the total equity as on Dec-24.
Some of the close peers are:
Company | Market Cap(₹ Cr) |
---|---|
37,287
|
|
27,803
|
|
27,702
|
|
24,500
|
Laurus Labs Ltd. | Ratios |
---|---|
Return on equity(%)
|
4.86
|
Operating margin(%)
|
8.61
|
Net Margin(%)
|
3.69
|
Dividend yield(%)
|
0.15
|
Yes, TTM profit after tax of Laurus Labs Ltd was ₹200 Cr.